Adverse effects of Heparin

Handbook of Experimental Pharmacology

Volumn 207, Issue , 2012, Pages 211-263

  Alban, S ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Bleeding; Heparin; Heparin induced thrombocytopenia (HIT); Osteoporosis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; ANTITHROMBIN; ARGATROBAN; CLOPIDOGREL; DABIGATRAN ETEXILATE; DANAPAROID; DIPYRIDAMOLE; ENOXAPARIN; EPTIFIBATIDE; FONDAPARINUX; GLUCOCORTICOID; HEPARIN; HIRULOG; INDOMETACIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; PRASUGREL; RETEPLASE; RIVAROXABAN; STREPTOKINASE; SULFINPYRAZONE; TENECTEPLASE; TICAGRELOR; TICLOPIDINE; TIROFIBAN; UNINDEXED DRUG; WARFARIN;

ACUTE CORONARY SYNDROME; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANAPHYLAXIS; ANTICOAGULATION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; BONE DENSITY; BRAIN HEMORRHAGE; CONTINUOUS INFUSION; DELAYED HYPERSENSITIVITY; DOSAGE SCHEDULE COMPARISON; DRUG DOSAGE FORM; DRUG DOSE; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; EPIDURAL ANESTHESIA; EPIDURAL HEMATOMA; FRACTURE NONUNION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPERKALEMIA; HYPOALDOSTERONISM; INJECTION SITE HEMATOMA; INJECTION SITE REACTION; LIVER TOXICITY; LUMBAR PUNCTURE; META ANALYSIS (TOPIC); METABOLIC ACIDOSIS; ORTHOPEDIC SURGERY; OSTEOLYSIS; OSTEOPOROSIS; PHASE 3 CLINICAL TRIAL (TOPIC); POINT OF CARE TESTING; POLYPHARMACY; PREGNANCY; PRIAPISM; PRIORITY JOURNAL; PROTEIN BINDING; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROPERITONEAL HEMORRHAGE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SIDE EFFECT; SKIN BIOPSY; SKIN DEFECT; SKIN NECROSIS; SKIN TEST; SPINAL HEMATOMA; SURGICAL TECHNIQUE; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; CHEMICALLY INDUCED DISORDER; HYPERSENSITIVITY; REVIEW; SKIN DISEASE; THROMBOCYTOPENIA;

HEMORRHAGE; HEPARIN; HUMANS; HYPERSENSITIVITY; OSTEOPOROSIS; RISK FACTORS; SKIN DISEASES; THROMBOCYTOPENIA;

EID: 84861893918     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/978-3-642-23056-1_10     Document Type: Article

References (215)

1. Alban S (2008a) Natural and synthetic glycosaminoglycans. Molecular characteristics as the basis of distinct drug profiles. Hamostaseologie 28:51-61
2. Alban S (2008b) Pharmacological strategies for inhibition of thrombin activity. Curr Pharm Des 14:1152-1175
3. Alban S, Greinacher A (2007) Role of sulfated polysaccharides in the pathogenesis of heparininduced thrombocytopenia. In: Warkentin TGA (ed) Heparin-induced thrombocytopenia, 4th edn. Informa Healthcare, New York, pp 167-186
4. Alberio L (2008) Heparin-induced thrombocytopenia: some working hypotheses on pathogenesis, diagnostic strategies and treatment. Curr Opin Hematol 15:456-464
5. Alexander KP, Chen AY, Roe MT, Newby LK, Gibson CM, Allen-LaPointe NM, Pollack C, Gibler WB, Ohman EM, Peterson ED (2005) Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 294:3108-3116
6. Alhenc-Gelas M, Jestin-Le Guernic C, Vitoux JF, Kher A, Aiach M, Fiessinger JN (1994) Adjusted versus fixed doses of the low-molecular-weight heparin fragmin in the treatment of deep vein thrombosis. Fragmin-Study Group. Thromb Haemost 71:698-702
7. Alikhan R, Cohen AT (2009) Heparin for the prevention of venous thromboembolism in general medical patients (excluding stroke and myocardial infarction). Cochrane Database Syst Rev: CD003747
8. Amiral J, Bridey F, Dreyfus M, Vissoc AM, Fressinaud E, Wolf M, Meyer D (1992) Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 68:95-96
9. Amiral J, Lormeau JC, Marfaing-Koka A, Vissac AM, Wolf M, Boyer-Neumann C, Tardy B, Herbert JM, Meyer D (1997) Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis 8:114-117
10. Anand SS, Yusuf S, Pogue J, Ginsberg JS, Hirsh J (2003) Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin. Circulation 107:2884-2888
11. Apsner R, Horl WH, Sunder-Plassmann G (2001) Dalteparin-induced alopecia in hemodialysis patients: reversal by regional citrate anticoagulation. Blood 97:2914-2915
12. Areapally GM, Poncz M, Cines DB (2007) Immune vascular injury in heparin-induced thrombocytopenia. In: Warkentin TGA (ed) heparin-induced thrombocytopenia, 4th edn. Informa Healthcare, New York, pp 209-226
13. Arepally GM, Mayer IM (2001) Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8. Blood 98:1252-1254
14. Arepally GM, Ortel TL (2006) Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med 355:809-817
15. Arora N, Goldhaber SZ (2006) Anticoagulants and transaminase elevation. Circulation 113: e698-e702
16. Barnes C, Deidun D, Hynes K, Monagle P (2000) Alopecia and dalteparin: A previously unreported association. Blood 96:1618-1619
17. Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernandez-Aviles F, Fox KA, Hasdai D, Ohman EM, Wallentin L, Wijns W (2007) Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 28:1598-1660
18. Bergqvist D (2004) Low molecular weight heparin for the prevention of venous thromboembolism after abdominal surgery. Br J Surg 91:965-974
19. Bernstein IL (1956) Anaphylaxis to heparin sodium; report of a case, with immunologic studies. J Am Med Assoc 161:1379-1381
20. Bick RL, Frenkel EP (1999) Clinical aspects of heparin-induced thrombocytopenia and thrombosis and other side effects of heparin therapy. Clin Appl Thromb Hemost 5(Suppl 1):S7-S15
21. Bircher AJ, Itin PH, Tsakiris DA, Surber C (1995) Delayed hypersensitivity to one low-molecularweight heparin with tolerance of other low-molecular-weight heparins. Br J Dermatol 132:461-463
22. Bircher AJ, Harr T, Hohenstein L, Tsakiris DA (2006) Hypersensitivity reactions to anticoagulant drugs: diagnosis and management options. Allergy 61:1432-1440
23. Blank M, Shoenfeld Y, Tavor S, Praprotnik S, Boffa MC, Weksler B, Walenga MJ, Amiral J, Eldor A (2002) Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells. Int Immunol 14:121-129
24. Borgen PO, Dahl OE, Reikeras O (2010) Preoperative versus postoperative initiation of dalteparin thromboprophylaxis in THA. Hip Int 20:301-307
25. Bounameaux H, Perrier A (2008) Duration of anticoagulation therapy for venous thromboembolism. Hematology Am Soc Hematol Educ Program: 252-258
26. Bryant A, Low J, Austin S, Joseph JE (2008) Timely diagnosis and management of heparininduced thrombocytopenia in a frequent request, low incidence single centre using clinical 4T's score and particle gel immunoassay. Br J Haematol 143:721-726
27. Budaj A, Eikelboom JW, Mehta SR, Afzal R, Chrolavicius S, Bassand JP, Fox KA, Wallentin L, Peters RJ, Granger CB, Joyner CD, Yusuf S (2009) Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. Eur Heart J 30:655-661
28. Carlin AJ, Farquharson RG, Quenby SM, Topping J, Fraser WD (2004) Prospective observational study of bone mineral density during pregnancy: low molecular weight heparin versus control. Hum Reprod 19:1211-1214
29. Carlson MK, Gleason PP, Sen S (2001) Elevation of hepatic transaminases after enoxaparin use: Case report and review of unfractionated and low-molecular-weight heparin-induced hepatotoxicity. Pharmacotherapy 21:108-113
30. Casele H, Haney EI, James A, Rosene-Montella K, Carson M Bone density changes in women who receive thromboprophylaxis in pregnancy. Am J Obstet Gynecol;195:1109-1113
31. Chernoff AI (1950) Anaphylactic reaction following injection of heparin. N Engl J Med 242:315-319
32. Chess ED et al (2011) Case study: Contamination of heparin with oversulfated chondroitin sulfate. In: Lever R, Mulloy B, Page CP (eds) Heparin - a century of progress. Springer, Heidelberg 99-125
33. Chong BH, Chong JJ (2010) Heparin-induced thrombocytopenia associated with fondaparinux. Clin Adv Hematol Oncol 8:63-65
34. Chong BH, Murray B, Berndt MC, Dunlop LC, Brighton T, Chesterman CN (1994) Plasma P-selectin is increased in thrombotic consumptive platelet disorders. Blood 83:1535-1541
35. Christiansen C (1995) Osteoporosis: diagnosis and management today and tomorrow. Bone 17:513S-516S
36. Cines DB, Rauova L, Arepally G, Reilly MP, McKenzie SE, Sachais BS, PonczM(2007) Heparininduced thrombocytopenia: An autoimmune disorder regulated through dynamic autoantigen assembly/disassembly. J Clin Apher 22:31-36
37. Crowther MA, Cook DJ, Albert M, Williamson D, Meade M, Granton J, Skrobik Y, Langevin S, Mehta S, Hebert P, Guyatt GH, Geerts W, Rabbat C, Douketis J, Zytaruk N, Sheppard J, Greinacher A, Warkentin TE (2010) The 4Ts scoring system for heparin-induced thrombocytopenia in medical-surgical intensive care unit patients. J Crit Care 25:287-293
38. Dahlman TC (1993) Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 168:1265-1270
39. Denys B, Devreese K (2009) A clinical-laboratory approach contributing to a rapid and reliable diagnosis of heparin-induced thrombocytopenia: An update. Thromb Res 124:642-643
40. Denys B, Stove V, Philippe J, Devreese K (2008) A clinical-laboratory approach contributing to a rapid and reliable diagnosis of heparin-induced thrombocytopenia. Thromb Res 123:137-145
41. Douketis JD, Berger PB, Dunn AS, Jaffer AK, Spyropoulos AC, Becker RC, Ansell J (2008) The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133:299S-339S
42. Drew PJ, Smith MJ, Milling MA (1999) Heparin-induced skin necrosis and low molecular weight heparins. Ann R Coll Surg Engl 81:266-269
43. Dukes GE Jr, Sanders SW, Russo J Jr, Swenson E, Burnakis TG, Saffle JR, Warden GD (1984) Transaminase elevations in patients receiving bovine or porcine heparin. Ann Intern Med 100:646-650
44. Dumaine R, Borentain M, Bertel O, Bode C, Gallo R, White HD, Collet JP, Steinhubl SR, Montalescot G (2007) Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials. Arch Intern Med 167:2423-2430
45. Eikelboom J (2007) Nonbleeding complications of unfractionated and low-molecular weight heparins. Clin Adv Hematol Oncol 5:871-873
46. Eikelboom JW, Quinlan DJ, O'Donnell M (2009) Major bleeding, mortality, and efficacy of fondaparinux in venous thromboembolism prevention trials. Circulation 120:2006-2011
47. EMA (2010) Arixtra, Fondaparinux - EMEA/H/C/000403-II/0045. EPAR - Product information 31/08/2010
48. EMEA/CHMP (2006) Guideline on clinical investigation of medicinal products for prophylaxis of venous thromboembolic risk in non-surgical patients. CPMP/EWP/6235/04
49. EMEA/CHMP (2007) Guideline on clinical investigation of medicinal products for prophylaxis of high intra- and post-operative venous thromboembolic risk. CPMP/EWP/707/98 Rev.1 corr
50. Eriksson BI, Borris L, Dahl OE, Haas S, Huisman MV, Kakkar AK, Misselwitz F, Kalebo P (2006) Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost 4:121-128
51. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Kalebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, Buller HR (2007) Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 5:2178-2185
52. Erkens PM, Prins MH (2010) Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev: CD001100
53. Folwarczna J, Janiec W, Sliwinski L (2004) Effects of heparin and low-molecular-weight heparins on bone mechanical properties in rats. Thromb Haemost 92:940-946
54. Folwarczna J, Sliwinski L, Janiec W, Pikul M (2005) Effects of standard heparin and low-molecular-weight heparins on the formation of murine osteoclasts in vitro. PR Pharmacol Rep 57:635-645
55. Gaigl Z, Pfeuffer P, Raith P, Brocker EB, Trautmann A (2005) Tolerance to intravenous heparin in patients with delayed-type hypersensitivity to heparins: A prospective study. Br J Haematol 128:389-392
56. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW (2008) Prevention of venous thromboembolism: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines (8th Edition). Chest 133:381S-453S
57. Gennari C, Martini G, Nuti R (1998) Secondary osteoporosis. Aging (Milano) 10:214-224
58. Gouin-Thibault I, Siguret V, Pautas E (2010) A need for evidence-based clinical practice guidelines for the use of heparins in the elderly. Clin Interv Aging 5:119-121
59. Greer I, Hunt BJ (2005) Low molecular weight heparin in pregnancy: Current issues. Br J Haematol 128:593-601
60. Greer IA, Nelson-Piercy C (2005) Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: A systematic review of safety and efficacy. Blood 106:401-407
61. Greinacher A (2006) Heparin-induced thrombocytopenia: frequency and pathogenesis. Pathophysiol Haemost Thromb 35:37-45
62. Greinacher A (2009) Heparin-induced thrombocytopenia. J Thromb Haemost 7(Suppl 1):9-12
63. Greinacher A, Farner B, Kroll H, Kohlmann T, Warkentin TE, Eichler P (2005) Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost 94:132-135
64. Greinacher A, Gopinadhan M, Gunther JU, Omer-Adam MA, Strobel U, Warkentin TE, Papastavrou G, Weitschies W, Helm CA (2006) Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies. Arterioscler Thromb Vasc Biol 26:2386-2393
65. Greinacher A, Juhl D, Strobel U, Wessel A, Lubenow N, Selleng K, Eichler P, Warkentin TE (2007) Heparin-induced thrombocytopenia: A prospective study on the incidence, plateletactivating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. J Thromb Haemost 5:1666-1673
66. Greinacher A, Alban S, Omer-Adam MA, Weitschies W, Warkentin TE (2008) Heparin-induced thrombocytopenia: A stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings. Thromb Res 122:211-220
67. Greinacher A, Kohlmann T, Strobel U, Sheppard JA, Warkentin TE (2009) The temporal profile of the anti-PF4/heparin immune response. Blood 113:4970-4976
68. Greinacher A, Althaus K, Krauel K, Selleng S (2010a) Heparin-induced thrombocytopenia. Hamostaseologie 30(17-8):20-28
69. Greinacher A, Ittermann T, Bagemuhl J, Althaus K, Furll B, Selleng S, Lubenow N, Schellong S, Sheppard JI, Warkentin TE (2010b) Heparin-induced thrombocytopenia: towards standardization of platelet factor 4/heparin antigen tests. J Thromb Haemost 8:2025-2031
70. Greten H, Schettler G, Mordasini R, Zipperle G, Klar E, Laible V (1978) Mechanism of action of synthetic heparinoids: results in patients with hypertriglyceridaemia (author's transl). Dtsch Med Wochenschr 103:204-211
71. Griffith GC, Nichols G Jr, Asher JD, Flanagan B (1965) Heparin osteoporosis. JAMA 193:91-94
72. Grims RH, Weger W, Reiter H, Arbab E, Kranke B, Aberer W (2007) Delayed-type hypersensitivity to low molecular weight heparins and heparinoids: Cross-reactivity does not depend on molecular weight. Br J Dermatol 157:514-517
73. Guevara A, Labarca J, Gonzalez-Martin G (1993) Heparin-induced transaminase elevations: A prospective study. Int J Clin Pharmacol Ther Toxicol 31:137-141
74. Haentjens P (1996) Thromboembolic prophylaxis in orthopaedic trauma patients: A comparison between a fixed dose and an individually adjusted dose of a low molecular weight heparin (nadroparin calcium). Injury 27:385-390
75. Handschin AE, Trentz O, Kock HJ, Wanner GA (2005a) Low molecular weight heparin-induced skin necrosis - a systematic review. Langenbecks Arch Surg 390:249-254
76. Handschin AE, Trentz OA, Hoerstrup SP, Kock HJ, Wanner GA, Trentz O (2005b) Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra) on human osteoblasts in vitro. Br J Surg 92:177-183
77. Handschin AE, Egermann M, Trentz O, Wanner GA, Kock HJ, Zund G, Trentz OA (2006) Cbfa-1 (Runx-2) and osteocalcin expression by human osteoblasts in heparin osteoporosis in vitro. Clin Appl Thromb Hemost 12:465-472
78. Harada N, Okajima K, Uchiba M (2006) Dalteparin, a low molecular weight heparin, attenuates inflammatory responses and reduces ischemia-reperfusion- induced liver injury in rats. Crit Care Med 34:1883-1891
79. Harr T, Scherer K, Tsakiris DA, Bircher AJ (2006) Immediate type hypersensitivity to low molecular weight heparins and tolerance of unfractioned heparin and fondaparinux. Allergy 61:787-788
80. Hawkins D, Evans J (2005) Minimising the risk of heparin-induced osteoporosis during pregnancy. Expert Opin Drug Saf 4:583-590
81. Heit JA, Berkowitz SD, Bona R, Cabanas V, Corson JD, Elliott CG, Lyons R (1997) Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: A double-blind, dose-ranging study. Ardeparin Arthroplasty Study Group. Thromb Haemost 77:32-38
82. Hinz P, Lubenow N, Wessel A, Greinacher A, Ekkernkamp A (2009) [Thrombosis prophylaxis in trauma surgery units in Germany: A survey]. Unfallchirurg 112(12):1029-1033
83. Hirschboeck JS, Madison FW, Pisciotta AV (1954) Alopecia and other toxic effects of heparin and synthetic heparinoids. Am J Med Sci 227:279-282
84. Hirsh J, Raschke R (2004) Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:188S-203S
85. Hirsh J, Warkentin TE, Raschke R, Granger C, Ohman EM, Dalen JE (1998) Heparin and lowmolecular- weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 114:489S-510S
86. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM, Dalen JE (2001) Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 119:64S-94S
87. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL (2000) The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 15:2-12
88. Hohenstein E, Tsakiris D, Bircher AJ (2004) Delayed-type hypersensitivity to the ultra-lowmolecular- weight heparin fondaparinux. Contact Dermatitis 51:149-151
89. Hui CK, Yuen MF, Ng IO, Tsang KW, Fong GC, Lai CL (2001) Low molecular weight heparininduced liver toxicity. J Clin Pharmacol 41:691-694
90. Hull RD, Pineo GF, MacIsaac S (2001) Low-molecular-weight heparin prophylaxis: preoperative versus postoperative initiation in patients undergoing elective hip surgery. Thromb Res 101: V155-V162
91. Hursting MJ, Soffer J (2009) Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in heparin-induced thrombocytopenia. Drug Saf 32:203-218
92. Irie A, Takami M, Kubo H, Sekino-Suzuki N, Kasahara K, Sanai Y (2007) Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity. Bone 41:165-174
93. Jappe U (2006) Allergy to heparins and anticoagulants with a similar pharmacological profile: An update. Blood Coagul Fibrinolysis 17:605-613
94. Kakkar VV, Kakkar S, Sanderson RM, Peers CE (1986) Efficacy and safety of two regimens of low molecular weight heparin fragment (Fragmin) in preventing postoperative venous thrombolism. Haemostasis 16(Suppl 2):19-24
95. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ (2008) Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines (8th Edition). Chest 133:454S-545S
96. Kelton JG, Warkentin TE (2008) Heparin-induced thrombocytopenia: A historical perspective. Blood 112:2607-2616
97. Kinnaird TD, Stabile E, Mintz GS, Lee CW, Canos DA, Gevorkian N, Pinnow EE, Kent KM, Pichard AD, Satler LF, Weissman NJ, Lindsay J, Fuchs S (2003) Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 92:930-935
98. Koch P, Munssinger T, Rupp-John C, Uhl K (2000) Delayed-type hypersensitivity skin reactions caused by subcutaneous unfractionated and low-molecular-weight heparins: tolerance of a new recombinant hirudin. J Am Acad Dermatol 42:612-619
99. Komericki P, Grims R, Kranke B, Aberer W (2007) Acute generalized exanthematous pustulosis from dalteparin. J Am Acad Dermatol 57:718-721
100. Krauel K, Furll B, Warkentin TE, Weitschies W, Kohlmann T, Sheppard JI, Greinacher A (2008) Heparin-induced thrombocytopenia-therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4-heparin complexes. J Thromb Haemost 6:2160-2167
101. Kukner A, Tore F, Firat T, Terzi EH, Oner H, Balaban YH, Ozogul C (2010) The preventive effect of low molecular weight heparin on CCL-induced necrosis and apoptosis in rat liver. Ann Hepatol 9:445-54
102. Lassen MR, Borris LC, Jensen HP, Poulsen KA, Ejstrud P, Andersen BS (2000) Dose relation in the prevention of proximal vein thrombosis with a low molecular weight heparin (tinzaparin) in elective hip arthroplasty. Clin Appl Thromb Hemost 6:53-57
103. Le Templier G, Rodger MA (2008) Heparin-induced osteoporosis and pregnancy. Curr Opin Pulm Med 14:403-407
104. Lefkou E, Khamashta M, Hampson G, Hunt BJ (2009) Review: low-molecular-weight heparininduced osteoporosis and osteoporotic fractures: A myth or an existing entity? Lupus 19:3-12
105. Leizorovicz A, Bara L, Samama MM, Haugh MC (1993) Factor Xa inhibition: Correlation between the plasma levels of anti-Xa activity and occurrence of thrombosis and haemorrhage. Haemostasis 23(Suppl 1):89-98
106. Lim W, Dentali F, Eikelboom JW, Crowther MA (2006) Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 144:673-684
107. Lindhoff-Last E, Piechottka GP, Rabe F, Bauersachs R (2000) Hirudin determination in plasma can be strongly influenced by the prothrombin level. Thromb Res 100:55-60
108. Lindner T, Cockbain AJ, El Masry MA, Katonis P, Tsiridis E, Schizas C (2008) The effect of anticoagulant pharmacotherapy on fracture healing. Expert Opin Pharmacother 9:1169-1187
109. Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A (2006) Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 4:759-765
110. Lobo B, Finch C, Howard A, Minhas S (2008) Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia. Thromb Haemost 99:208-214
111. Lopez LM (2001) Low-molecular-weight heparins are essentially the same for treatment and prevention of venous thromboembolism. Pharmacotherapy 21:56-61, discussion 71S-72S
112. Lopez S, Torres MJ, Rodriguez-Pena R, Blanca-Lopez N, Fernandez TD, Antunez C, Canto G, de Luque V, Mayorga C (2009) Lymphocyte proliferation response in patients with delayed hypersensitivity reactions to heparins. Br J Dermatol 160:259-265
113. Louzada ML, Majeed H, Wells PS (2009) Efficacy of low- molecular- weight- heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: A systematic review of randomized controlled trials. Thromb Res 123:837-844
114. Lubenow N, Kempf R, Eichner A, Eichler P, Carlsson LE, Greinacher A (2002) Heparin-induced thrombocytopenia: temporal pattern of thrombocytopenia in relation to initial use or reexposure to heparin. Chest 122:37-42
115. Lubenow N, Hinz P, Thomaschewski S, Lietz T, Vogler M, Ladwig A, Junger M, Nauck M, Schellong S, Wander K, Engel G, Ekkernkamp A, Greinacher A (2010) The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia. Blood 115:1797-1803
116. Ludwig RJ, Schindewolf M, Alban S, Kaufmann R, Lindhoff-Last E, Boehncke WH (2005) Molecular weight determines the frequency of delayed type hypersensitivity reactions to heparin and synthetic oligosaccharides. Thromb Haemost 94:1265-1269
117. Ludwig RJ, Schindewolf M, Utikal J, Lindhoff-Last E, Boehncke WH (2006) Management of cutaneous type IV hypersensitivity reactions induced by heparin. Thromb Haemost 96:611-617
118. Ludwig RJ, Schindewolf M, Lindhoff-Last E, Boehncke WH (2008) The influence of heparin's molecular weight and the incidence of delayed type hypersensitivity reactions revisited; in response to Grims et al., Br J Dermatol 2007; 157:514-17. Br J Dermatol 158:849-851
119. Macie C, Forbes L, Foster GA, Douketis JD (2004) Dosing practices and risk factors for bleeding in patients receiving enoxaparin for the treatment of an acute coronary syndrome. Chest 125:1616-1621
120. Magee KD, Campbell SG, Moher D, Rowe BH (2008) Heparin versus placebo for acute coronary syndromes. Cochrane Database Syst Rev: CD003462
121. Manoukian SV, Voeltz MD, Eikelboom J (2007) Bleeding complications in acute coronary syndromes and percutaneous coronary intervention: predictors, prognostic significance, and paradigms for reducing risk. Clin Cardiol 30:II24-II34
122. Martel N, Lee J, Wells PS (2005) Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: A meta-analysis. Blood 106:2710-2715
123. Matziolis G, Perka C, Disch A, Zippel H (2003) Effects of fondaparinux compared with dalteparin, enoxaparin and unfractionated heparin on human osteoblasts. Calcif Tissue Int 73:370-379
124. Melloni C, Alexander KP, Chen AY, Newby LK, Roe MT, Allen LaPointe NM, Pollack CV Jr, Gibler WB, Ohman EM, Peterson ED (2008) Unfractionated heparin dosing and risk of major bleeding in non-ST-segment elevation acute coronary syndromes. Am Heart J 156:209-215
125. MHRA (2011) Clexane. Summary of product characteristics. http://www.sanofi-aventis.co.uk/ products/Clexane-SPC.pdf
126. Miller PD (2006) Guidelines for the diagnosis of osteoporosis: T-scores vs fractures. Rev Endocr Metab Disord 7:75-89
127. Mismetti P, Laporte S, Darmon JY, Buchmuller A, Decousus H (2001) Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 88:913-930
128. Monreal M, Lafoz E, Salvador R, Roncales J, Navarro A (1989) Adverse effects of three different forms of heparin therapy: thrombocytopenia, increased transaminases, and hyperkalaemia. Eur J Clin Pharmacol 37:415-418
129. Monreal M, Lafoz E, Olive A, del Rio L, Vedia C (1994) Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 71:7-11
130. Muir JM, Andrew M, Hirsh J, Weitz JI, Young E, Deschamps P, Shaughnessy SG (1996) Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo. Blood 88:1314-1320
131. Muir JM, Hirsh J, Weitz JI, Andrew M, Young E, Shaughnessy SG (1997) A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats. Blood 89:3236-3242
132. Mulloy B (2005) The specificity of interactions between proteins and sulfated polysaccharides. An Acad Bras Cienc 77:651-664
133. Murphy SA, Gibson CM, Morrow DA, Van de Werf F, Menown IB, Goodman SG, Mahaffey KW, Cohen M, McCabe CH, Antman EM, Braunwald E (2007) Efficacy and safety of the lowmolecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: A meta-analysis. Eur Heart J 28:2077-2086
134. Nelson-Piercy C (1997) Hazards of heparin: Allergy, heparin-induced thrombocytopenia and osteoporosis. Baillieres Clin Obstet Gynaecol 11:489-509
135. Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ (1991) Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood 78:2337-2343
136. Oie CI, Olsen R, Smedsrod B, Hansen JB (2008) Liver sinusoidal endothelial cells are the principal site for elimination of unfractionated heparin from the circulation. Am J Physiol Gastrointest Liver Physiol 294:G520-G528
137. Palmer AJ, Koppenhagen K, Kirchhof B, Weber U, Bergemann R (1997) Efficacy and safety of low molecular weight heparin, unfractionated heparin and warfarin for thrombo-embolism prophylaxis in orthopaedic surgery: A meta-analysis of randomised clinical trials. Haemostasis 27:75-84
138. Paus R (1991) Hair growth inhibition by heparin in mice: A model system for studying the modulation of epithelial cell growth by glycosaminoglycans? Br J Dermatol 124:415-422
139. Pettila V, Kaaja R, Leinonen P, Ekblad U, Kataja M, Ikkala E (1999) Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thromb Res 96:275-282
140. Pettila V, Leinonen P, Markkola A, Hiilesmaa V, Kaaja R (2002) Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb Haemost 87:182-186
141. Pouplard C, Iochmann S, Renard B, Herault O, Colombat P, Amiral J, Gruel Y (2001) Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. Blood 97:3300-3302
142. Pouplard C, Gueret P, Fouassier M, Ternisien C, Trossaert M, Regina S, Gruel Y (2007) Prospective evaluation of the '4Ts' score and particle gel immunoassay specific to heparin/ PF4 for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 5:1373-1379
143. Pratt DS, Kaplan MM (2000) Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 342:1266-1271
144. Qian Y, Pan J, Zhou X, Weiser P, Lu H, Zhang L (2010) Molecular mechanism underlines heparininduced thrombocytopenia and thrombosis. Prog Mol Biol Transl Sci 93:395-421
145. Rajgopal R, Bear M, Butcher MK, Shaughnessy SG (2008) The effects of heparin and low molecular weight heparins on bone. Thromb Res 122:293-298
146. Rao SV, Eikelboom J, Steg PG, Lincoff AM, Weintraub WS, Bassand JP, Rao AK, Gibson CM, Petersen JL, Mehran R, Manoukian SV, Charnigo R, Lee KL, Moscucci M, Harrington RA (2009) Standardized reporting of bleeding complications for clinical investigations in acute coronary syndromes: A proposal from the academic bleeding consensus (ABC) multidisciplinary working group. Am Heart J 158(881-886):e1
147. Rapaport SI, Vermylen J, Hoylaerts M, Saito H, Hirsh J, Bates S, Dahlback B, Poller L (2004) The multiple faces of the partial thromboplastin time APTT. J Thromb Haemost 2:2250-2259
148. Raskob GE, Hirsh J (2003) Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery. Chest 124:379S-385S
149. Rauova L, Poncz M, McKenzie SE, Reilly MP, Arepally G, Weisel JW, Nagaswami C, Cines DB, Sachais BS (2005) Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood 105:131-138
150. Rauova L, Zhai L, Kowalska MA, Arepally GM, Cines DB, Poncz M (2006) Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. Blood 107:2346-2353
151. Riess H, Koppenhagen K, Tolle A, Kemkes-Matthes B, Grave M, Patek F, Drexler M, Siemens HJ, Harenberg J, Weidinger G, Brom J, Haas S (2003) Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis. Thromb Haemost 90:252-259
152. Riess H, Haas S, Tebbe U, Gerlach HE, Abletshauser C, Sieder C, Rossol S, Pfeiffer B, Schellong SM (2010) A randomized, double-blind study of certoparin vs. unfractionated heparin to prevent venous thromboembolic events in acutely ill, non-surgical patients: CERTIFY Study. J Thromb Haemost 8:1209-1215
153. Rodger MA, Kahn SR, Cranney A, Hodsman A, Kovacs MJ, Clement AM, Lazo-Langner A, Hague WM (2007) Long-term dalteparin in pregnancy not associated with a decrease in bone mineral density: substudy of a randomized controlled trial. J Thromb Haemost 5:1600-1606
154. Ruiz-Gimenez N, Suarez C, Gonzalez R, Nieto JA, Todoli JA, Samperiz AL, Monreal M (2008) Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 100:26-31
155. Russo MW, Watkins PB (2004) Are patients with elevated liver tests at increased risk of druginduced liver injury? Gastroenterology 126:1477-1480
156. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson CG, Turpie AG, Weisslinger N (1999) A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 341:793-800
157. Sarris E, Tsele E, Bagiatoudi G, Salpigidis K, Stavrianaki D, Kaklamanis L, Siakotos M (2003) Diffuse alopecia in a hemodialysis patient caused by a low-molecular-weight heparin, tinzaparin. Am J Kidney Dis 41:E15
158. Savi P, Chong BH, Greinacher A, Gruel Y, Kelton JG, Warkentin TE, Eichler P, Meuleman D, Petitou M, Herault JP, Cariou R, Herbert JM (2005) Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: A blinded comparative multicenter study with unfractionated heparin. Blood 105:139-144
159. Scherer K, Tsakiris DA, Bircher AJ (2008) Hypersensitivity reactions to anticoagulant drugs. Curr Pharm Des 14:2863-2873
160. Schindewolf M, Ludwig RJ (2010) Need for an increasing awareness for heparin-induced skin lesions. Expert Rev Dermatol 5:1-3
161. Schindewolf M, Schwaner S, Wolter M, Kroll H, Recke A, Kaufmann R, Boehncke WH, Lindhoff-Last E, Ludwig RJ (2009) Incidence and causes of heparin-induced skin lesions. CMAJ 181:477-481
162. Schindewolf M, Kroll H, Ackermann H, Garbaraviciene J, Kaufmann R, Boehncke WH, Ludwig RJ, Lindhoff-Last E (2010a) Heparin-induced non-necrotizing skin lesions: rarely associated with heparin-induced thrombocytopenia. J Thromb Haemost 8:1486-1491
163. Schindewolf M, Scheuermann J, Kroll H, Garbaraviciene J, Hecking C, Marzi I, Wolter M, Kaufmann R, Boehncke WH, Lindhoff-Last E, Ludwig RJ (2010b) Low allergenic potential with fondaparinux: results of a prospective investigation. Mayo Clin Proc 85:913-919
164. Schulman S, Beyth RJ, Kearon C, Levine MN (2008) Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133:257S-298S
165. Seitz CS, Brocker EB, Trautmann A (2008) Management of allergy to heparins in postoperative care: subcutaneous allergy and intravenous tolerance. Dermatol Online J 14:4
166. Senior J (2003) Regulatory perspectives. In: Kaplowitz N, DeLeve LD (eds) Drug-induced liver disease. Marcel Dekker, New York, pp 739-754
167. Shantsila E, Lip GY, Chong BH (2009) Heparin-induced thrombocytopenia. A contemporary clinical approach to diagnosis and management. Chest 135:1651-1664
168. Shaughnessy SG, Young E, Deschamps P, Hirsh J (1995) The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria. Blood 86:1368-1373
169. Shaughnessy SG, Hirsh J, Bhandari M, Muir JM, Young E, Weitz JI (1999) A histomorphometric evaluation of heparin-induced bone loss after discontinuation of heparin treatment in rats. Blood 93:1231-1236
170. Stein PD, Hull RD, Matta F, Yaekoub AY, Liang J (2009) Incidence of thrombocytopenia in hospitalized patients with venous thromboembolism. Am J Med 122:919-930
171. Suh JS, Aster RH, Visentin GP (1998) Antibodies from patients with heparin-induced thrombocytopenia/ thrombosis recognize different epitopes on heparin: platelet factor 4. Blood 91:916-922
172. Suzuki S, Koide M, Sakamoto S, Yamamoto S, Matsuo M, Fujii E, Matsuo T (1997) Early onset of immunological heparin-induced thrombocytopenia in acute myocardial infarction. Blood Coagul Fibrinolysis 8:13-15
173. Szolar-Platzer C, Aberer W, Kranke B (2000) Delayed-type skin reaction to the heparinalternative danaparoid. J Am Acad Dermatol 43:920-922
174. Taha MO, Goncalves PF, Vidigal RO, Sacchi GP, Pinheiro FG, Brandao LS, Feguri S, Moraes-Filho AM, Ghadie MM, Magalhaes KG, Simoes MJ, Tersariol IL, Monteiro HP, Oliveira-Junior IS, Jurkiewicz A, Caricati-Neto A (2009) Protective effects of heparin on hepatic ischemia and reperfusion lesions in rabbits. Transplant Proc 41:812-815
175. Tardy-Poncet B, Piot M, Chapelle C, France G, Campos L, Garraud O, Decousus H, Mismetti P, Tardy B (2009) Thrombin generation and heparin-induced thrombocytopenia. J Thromb Haemost 7:1474-1481
176. Testroote M, Stigter W, de Visser DC, Janzing H (2008) Low molecular weight heparin for prevention of venous thromboembolism in patients with lower-leg immobilization. Cochrane Database Syst Rev: CD006681
177. Thery C, Simonneau G, Meyer G, Helenon O, Bridey F, Armagnac C, d'Azemar P, Coquart JP (1992) Randomized trial of subcutaneous low-molecular-weight heparin CY 216 (Fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. A dose-ranging study. Circulation 85:1380-1389
178. TIMI 11A Trial Investigators (1997) Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. The Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 29:1474-1482
179. Tooher R, Gates S, Dowswell T, Davis LJ (2010) Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. Cochrane Database Syst Rev: CD001689
180. Trautmann A, Seitz CS (2009) Heparin allergy: delayed-type non-IgE-mediated allergic hypersensitivity to subcutaneous heparin injection. Immunol Allergy Clin North Am 29:469-480
181. Trautmann A, Seitz CS (2010) The complex clinical picture of side effects to anticoagulation. Med Clin North Am 94:821-834, xii-iii
182. Trouvin AP, Goeb V (2010) Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: maintaining the balance to prevent bone loss. Clin Interv Aging 5:345-354
183. Trujillo-Santos J, Nieto JA, Tiberio G, Piccioli A, Di Micco P, Prandoni P, Monreal M (2008) Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 100:435-439
184. Tudhope GR, Cohen H, Meikle RW (1958) Alopecia following treatment with dextran sulphate and other anticoagulant drugs. Br Med J 1:1034-1037
185. Turcotte JG, Kraft RO, Fry WJ (1965) Heparin reactions in patients with vascular disease. Arch Surg 90:375-379
186. Turpie AG, Bauer KA, Eriksson BI, Lassen MR (2002) Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: A meta-analysis of 4 randomized double-blind studies. Arch Intern Med 162:1833-1840
187. Umlas J, Harken DE (1988) Warfarin-induced alopecia. Cutis 42:63-64
188. Van De Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, Filippatos G, Fox K, Huber K, Kastrati A, Rosengren A, Steg PG, Tubaro M, Verheugt F, Weidinger F, Weis M, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Aguirre FV, Al-Attar N, Alegria E, Andreotti F, Benzer W, Breithardt O, Danchin N, Di Mario C, Dudek D, Gulba D, Halvorsen S, Kaufmann P, Kornowski R, Lip GY, Rutten F (2008) Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 29:2909-2945
189. van der Wiel HE, Lips P, Huijgens PC, Netelenbos JC (1993) Effects of short-term low-dose heparin administration on biochemical parameters of bone turnover. Bone Miner 22:27-32
190. van Dongen CJ, MacGillavry MR, Prins MH (2005) Once versus twice daily LMWH for the initial treatment of venous thromboembolism. Cochrane Database Syst Rev: CD003074
191. Vik A, Brodin E, Sveinbjornsson B, Hansen JB (2007) Heparin induces mobilization of osteoprotegerin into the circulation. Thromb Haemost 98:148-154
192. Wang YY, Po HL (2006) Enoxaparin-induced alopecia in patients with cerebral venous thrombosis. J Clin Pharm Ther 31:513-517
193. Warkentin TE (1996) Heparin-induced skin lesions. Br J Haematol 92:494-497
194. Warkentin TE (2003) Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 121:535-555
195. Warkentin TE (2006) Think of HIT. Hematology Am Soc Hematol Educ Program: 408-414
196. Warkentin TE (2007) Clinical picture of heparin-induced thrombocytopenia. In: Warkentin TGA (ed) Heparin-induced thrombocytopenia, 4th edn. Informa Healthcare, New York, pp 21-66
197. Warkentin TE (2008) Fondaparinux versus direct thrombin inhibitor therapy for the management of heparin-induced thrombocytopenia (HIT) - bridging the River Coumarin. Thromb Haemost 99:2-3
198. Warkentin TE (2010) Agents for the treatment of heparin-induced thrombocytopenia. Hematol Oncol Clin North Am 24:755-775, ix
199. Warkentin TE, Greinacher A (2009) Heparin-induced anaphylactic and anaphylactoid reactions: two distinct but overlapping syndromes. Expert Opin Drug Saf 8:129-144
200. Warkentin TE, Heddle NM (2003) Laboratory diagnosis of immune heparin-induced thrombocytopenia. Curr Hematol Rep 2:148-157
201. Warkentin TE, Kelton JG (2001) Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 344:1286-1292
202. Warkentin TE, Linkins LA (2010) Non-necrotizing heparin-induced skin lesions and the 4T's score. J Thromb Haemost 8:1483-1485
203. Warkentin TE, Sheppard JI (1999) Generation of platelet-derived microparticles and procoagulant activity by heparin-induced thrombocytopenia IgG/serum and other IgG platelet agonists: A comparison with standard platelet agonists. Platelets 10:319-326
204. Warkentin TE, Elavathil LJ, Hayward CP, Johnston MA, Russett JI, Kelton JG (1997) The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 127:804-812
205. Warkentin TE, Chong BH, Greinacher A (1998) Heparin-induced thrombocytopenia: towards consensus. Thromb Haemost 79:1-7
206. Warkentin TE, Cook RJ, Marder VJ, Sheppard JA, Moore JC, Eriksson BI, Greinacher A, Kelton JG (2005a) Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 106:3791-3796
207. Warkentin TE, Roberts RS, Hirsh J, Kelton JG (2005b) Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: A nested cohort study. Chest 127:1857-1861
208. Warkentin TE, Sheppard JA, Moore JC, Moore KM, Sigouin CS, Kelton JG (2005c) Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? J Lab Clin Med 146:341-346
209. Warkentin TE, Sheppard JA, Sigouin CS, Kohlmann T, Eichler P, Greinacher A (2006) Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood 108:2937-2941
210. Warkentin TE, Greinacher A, Koster A, Lincoff AM (2008a) Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133:340S-380S
211. Warkentin TE, Makris M, Jay RM, Kelton JG (2008b) A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia. Am J Med 121:632-636
212. Warkentin TE, Sheppard JA, Moore JC, Cook RJ, Kelton JG (2009) Studies of the immune response in heparin-induced thrombocytopenia. Blood 113:4963-4969
213. Warkentin TE, Cook RJ, Marder VJ, Greinacher A (2010) Anti-PF4/heparin antibody formation postorthopedic surgery thromboprophylaxis: the role of non-drug risk factors and evidence for a stoichiometry-based model of immunization. J Thromb Haemost 8:504-512
214. Zcharia E, Philp D, Edovitsky E, Aingorn H, Metzger S, Kleinman HK, Vlodavsky I, Elkin M (2005) Heparanase regulates murine hair growth. Am J Pathol 166:999-1008
215. Zikria JC, Ansell J (2009) Oral anticoagulation with factor Xa and thrombin inhibitors: On the threshold of change. Curr Opin Hematol 16:347-356